PBS broadens access to COPD triple therapy and lung cancer immunotherapy
By Michael Woodhead
20 Feb 2020
For COPD patients the PBS is to remove the clinical criteria restricting access to patients with a FEV1 <50% of predicted for triple therapy Trelegy (fluticasone furoate with umeclidinium and vilanterol) from 1 March 2020. The move is expected to allow more than 16,000 patients per year to access triple therapy. It follows a recommendation ...